Related Experiment Videos
Anti-gram-positive agents. What we have and what we would like
1Department of Microbiology, University College London Hospitals, England.
Abstract:
The usefulness of many anti-Gram-positive antibiotics is being compromised by the spread of antibiotic resistance in bacteria. The most reliable agents for serious infections are the glycopeptide agents vancomycin and teicoplanin. The appropriate maintenance dosage for teicoplanin in serious infections is 6 mg/kg/day, i.e. usually 400 mg/day. There are 3 exceptions for which the daily maintenance dosage should be 12 mg/kg/day and these are intravenous drug abusers, septic arthritis (but not osteomyelitis), and Staphylococcus aureus endocarditis treated with teicoplanin monotherapy. When teicoplanin is given at these doses, it achieves clinical and bacteriological results that are equivalent to those obtained with vancomycin, irrespective of pathogen or type of infection. The toxicity profile favours teicoplanin over vancomycin, especially when other, potentially toxic, drugs are coadministered. Teicoplanin also has an advantage in terms of ease and convenience of administration, which, together with its lack of need for routine blood level monitoring, facilitates its use outside hospital. New agents hold some promise for the future; however, oral agents, if developed, could present the risk of being overused, which might compromise their long term utility.
Insights
Teicoplanin is an effective glycopeptide antibiotic for serious Gram-positive infections, offering advantages over vancomycin. Its favorable toxicity and administration profile support its use, even in challenging cases.
Area of Science:
- Pharmacology
- Infectious Diseases
- Microbiology
Background:
- Increasing antibiotic resistance in Gram-positive bacteria compromises treatment options.
- Glycopeptide antibiotics, vancomycin and teicoplanin, remain crucial for serious infections.
- Optimizing teicoplanin dosing is essential for maximizing efficacy and minimizing resistance.
Purpose of the Study:
- To evaluate the efficacy and safety of teicoplanin compared to vancomycin.
- To define appropriate dosing strategies for teicoplanin in various serious infections.
- To highlight teicoplanin's advantages in specific patient populations and administration contexts.
Main Methods:
- Review of clinical data and pharmacokinetic/pharmacodynamic principles for teicoplanin and vancomycin.
- Analysis of treatment outcomes in serious Gram-positive bacterial infections.
- Comparison of toxicity profiles and administration requirements between the two agents.
Main Results:
- Teicoplanin at 6 mg/kg/day (or 400 mg/day) is effective for most serious infections.
- Higher teicoplanin doses (12 mg/kg/day) are required for intravenous drug abusers, septic arthritis, and Staphylococcus aureus endocarditis monotherapy.
- Teicoplanin demonstrates equivalent clinical and bacteriological outcomes to vancomycin with a better safety profile and easier administration.
Conclusions:
- Teicoplanin is a reliable and advantageous alternative to vancomycin for treating serious Gram-positive infections.
- Specific dosing adjustments for teicoplanin are necessary in certain high-risk patient groups.
- Teicoplanin's favorable characteristics facilitate outpatient use and may reduce the risk of future antibiotic resistance.